Hot Features
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailabl... BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.99 | -12.2071516646 | 8.11 | 8.325 | 7.07 | 288075 | 7.48452271 | CS |
| 4 | -0.97 | -11.9901112485 | 8.09 | 9.26 | 7.07 | 384751 | 8.4079258 | CS |
| 12 | -1.7 | -19.2743764172 | 8.82 | 9.73 | 7.07 | 369573 | 8.65440564 | CS |
| 26 | -5.86 | -45.1463790447 | 12.98 | 14.6 | 7.07 | 316828 | 9.92078523 | CS |
| 52 | -2.37 | -24.9736564805 | 9.49 | 14.87 | 7.07 | 282703 | 10.39059169 | CS |
| 156 | -2.37 | -24.9736564805 | 9.49 | 14.87 | 7.07 | 282703 | 10.39059169 | CS |
| 260 | -2.37 | -24.9736564805 | 9.49 | 14.87 | 7.07 | 282703 | 10.39059169 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.